Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 6
Can you import Retatrutide into the US?
Retatrutide is not FDA approved, cannot be compounded, and does not fit the ordinary personal-import route promoted by research sellers.
What Retatrutide actually costs in the US
No official US Retatrutide price exists because there is no FDA-approved pack. Seller quotes, trial supply and forecasts are different things.
Retatrutide US status: what changed
Retatrutide remains investigational and unapproved in the US. Phase 3 news and FDA enforcement messaging changed, not retail status.
Can you import Semaglutide into the US?
FDA-approved semaglutide exists in the US, but that does not make foreign pens, compounded vials or research products freely importable.
DIAL2 risk after semaglutide
A two-year cohort tracked DIAL2-predicted risk after semaglutide, empagliflozin, or both. It did not measure cardiovascular events.
GLP-1 Drugs and the FDA Eye Warning
The FDA now requires GLP-1 drug labels to warn about a potential risk of NAION, a rare condition that can cause sudden vision loss.
What Kuwait Women Knew About GLP-1s
A Kuwait survey found high tirzepatide and semaglutide awareness, but sharp differences in information sources and risk perceptions.
Foundayo and sleep apnea trial results
Two phase 3 trials found that oral orforglipron reduced sleep-apnea events, but the result is not a new FDA indication.
Peptides and Male Sexual Dysfunction
A systematic review found the clearest erectile signal for melanocortin agonists, but the male evidence remains small, varied and short term.
GLP-1 weight loss: strength versus mass
A 2026 review argues that lean-mass scans cannot show whether GLP-1 weight loss is reducing strength or physical function.
GLP-1 Medicines, Uric Acid and Gout
A meta-analysis links GLP-1-based therapy with modest uric-acid reductions and fewer gout flares, but dedicated gout trials are still missing.
HIV weight care: GLP-1s and tesamorelin
A 2026 review separates general obesity care from HIV-specific evidence for GLP-1 therapies, tesamorelin and body-composition outcomes.